Elicio Therapeutics (ELTX) Research & Development (2020 - 2026)

Elicio Therapeutics has reported Research & Development for 7 years, with the latest figure at $6.8 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 13.13% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $23.9 million (down 29.5% YoY), and the FY2025 full-year result was $24.9 million, down 26.01% from the prior year.
• Research & Development for Q1 2026 stood at $6.8 million, up from $5.1 million in the prior quarter.
• The five-year high for Research & Development was $11.7 million in Q1 2022, with the low at $4.3 million in Q4 2022.
• Historically, Research & Development has averaged $6.8 million across 5 years, with a median of $6.8 million in 2026.
• Annual changes were most pronounced in 2022 — Research & Development tumbled 65.43% — and 2024, when it soared 73.93%.
• Elicio Therapeutics' Research & Development stood at $4.3 million in 2022, then soared by 43.52% to $6.2 million in 2023, then soared by 73.93% to $10.7 million in 2024, then tumbled by 52.56% to $5.1 million in 2025, then surged by 33.01% to $6.8 million in 2026.
• The last three Research & Development figures came in at $6.8 million (Q1 2026), $5.1 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.